The Midwest Center for Stress and Anxiety Re-launches Website for Stress, Anxiety, and Depression.
LOS ANGELES, Feb. 18 /PRNewswire/ -- The Midwest Center for Stress and Anxiety announced today the re-launch of its website, http://www.stresscenter.com/, the premier online destination for news, information and solutions for coping with stress, anxiety and depression. The new site features an enhanced user interface with access to articles...

Cyberonics Provides Business Update on Depression Clinical Trial.
HOUSTON, Jan. 7 /PRNewswire-FirstCall/ -- Cyberonics, Inc. today announced that it has made a proposal to the U.S. Food and Drug Administration ("FDA") to amend the protocol of its post-market dosing study (D-21) in depression patients treated with VNS TherapyTM. Based on a reassessment of the study...

Hot flashes don't cause depression in menopause.
SAN FRANCISCO -- Hot flashes may not necessarily be a cause of depressive symptoms, according to a study that followed women in the menopausal transition for 10 years. "We were interested in whether these symptoms were more likely to occur concurrently and which was more likely to...

AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration.
Agreement includes research collaboration to generate follow-up TRI compounds WILMINGTON, Del., Feb. 9 /PRNewswire-FirstCall/ -- AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo...

Trial news: Cyberonics seeks approval for reduction in number of trial patients.
Specialist in neuromodulation, Cyberonics Inc, said it is waiting for a decision from the US Food and Drug Administration (FDA), concerning its post-market dosing study in patients suffering from depression. They are being treated with vagus nerve stimulation (VNS) therapy, developed by Cyberonics. VNS therapy has FDA...

Neural circuits foster oversensitivity: borderline personality patients activate brain in specific ways.
People diagnosed with the mental ailment known as borderline personality disorder hemorrhage emotion. Real or perceived rejections, losses or even minor slights trigger depression and other volatile reactions that can lead to suicide. New brain-imaging research suggests that in such people specific neural circuits foster extreme emotional...

Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R).
LONDON, February 19 /PRNewswire-FirstCall/ -- - Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede...

FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder.
TITUSVILLE, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that the Food and Drug Administration (FDA) has asked for additional information regarding the company's supplemental New Drug Application (sNDA) for RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection. The sNDA, submitted in April 2008,...

Anavex scales up synthesis of ANAVEX 2-73 for Phase 1 Alzheimer's disease study.
ATHENS, Greece, Feb. 2 /PRNewswire-FirstCall/ -- Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB ("Syntagon") for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease. ANAVEX 2-73 is scheduled to commence Phase 1...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R).
TITUSVILLE, N.J., Feb. 6 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for patients diagnosed with schizophrenia or schizoaffective disorder. ...